# COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222

> **NCT04864561** · PHASE3 · COMPLETED · sponsor: **Valneva Austria GmbH** · enrollment: 4034 (actual)

## Conditions studied

- SARS-CoV-2 Virus Infection

## Interventions

- **BIOLOGICAL:** VLA2001
- **BIOLOGICAL:** AZD1222
- **BIOLOGICAL:** VLA2001 - adolescent part
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04864561
- **Lead sponsor:** Valneva Austria GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-26
- **Primary completion:** 2021-07-19
- **Final completion:** 2023-03-13
- **Target enrollment:** 4034 (ACTUAL)
- **Last updated:** 2023-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04864561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04864561, "COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT04864561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*